Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat.

Evaluating the risk of chemical carcinogenesis has long been a challenge owing to the protracted nature of the pathology and the limited translatability of animal models. Although numerous short-term in vitro and in vivo assays have been developed, they have failed to reliably predict the carcinogenicity of nongenotoxic compounds. Extending upon previous microarray work (Fielden, M. R., Nie, A., McMillian, M., Elangbam, C. S., Trela, B. A., Yang, Y., Dunn, R. T., II, Dragan, Y., Fransson-Stehen, R., Bogdanffy, M., et al. (2008). Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol. Sci. 103, 28-34), we have developed and extensively evaluated a quantitative PCR-based signature to predict the potential for nongenotoxic compounds to induce liver tumors in the rat as a first step in the safety assessment of potential nongenotoxic carcinogens. The training set was derived from liver RNA from rats treated with 72 compounds and used to develop a 22-gene signature on the TaqMan array platform, providing an economical and standardized assay protocol. Independent testing on over 900 diverse samples (66 compounds) confirmed the interlaboratory precision of the assay and its ability to predict known nongenotoxic hepatocarcinogens (NGHCs). When tested under different experimental designs, strains, time points, dose setting criteria, and other preanalytical processes, the signature sensitivity and specificity was estimated to be 67% (95% confidence interval [CI] = 38-88%) and 59% (95% CI = 44-72%), respectively, with an area under the receiver operating characteristic curve of 0.65 (95% CI = 0.46-0.83%). Compounds were best classified using expression data from short-term repeat dose studies; however, the prognostic expression changes appeared to be preserved after longer term treatment. Exploratory evaluations also revealed that different modes of action for nongenotoxic and genotoxic compounds can be discriminated based on the expression of specific genes. These results support a potential early preclinical testing paradigm to catalyze broader understanding of putative NGHCs.

[1]  Russell S. Thomas,et al.  Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  M. Waters,et al.  Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. , 2010, Mutation research.

[3]  Pedro Romero,et al.  Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens. , 2010, Regulatory toxicology and pharmacology : RTP.

[4]  T. Chen,et al.  Pravastatin Attenuates Carboplatin-Induced Nephrotoxicity in Rodents via Peroxisome Proliferator-Activated Receptor α-Regulated Heme Oxygenase-1 , 2010, Molecular Pharmacology.

[5]  S. Auerbach,et al.  Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. , 2010, Toxicology and applied pharmacology.

[6]  S. Cohen Evaluation of Possible Carcinogenic Risk to Humans Based on Liver Tumors in Rodent Assays , 2010, Toxicologic pathology.

[7]  T. Nikolskaya,et al.  Use of short-term transcriptional profiles to assess the long-term cancer-related safety of environmental and industrial chemicals. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  A. Martelli,et al.  Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. , 2009, Mutation research.

[9]  R. Snyder,et al.  Prediction of non-genotoxic carcinogenesis in rats using changes in gene expression following acute dosing. , 2008, Chemico-biological interactions.

[10]  N. Kiyosawa,et al.  A toxicogenomics approach for early assessment of potential non-genotoxic hepatocarcinogenicity of chemicals in rats. , 2008, Toxicology.

[11]  M. Fielden,et al.  Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  J. Ward Value of rodent carcinogenesis bioassays. , 2008, Toxicology and applied pharmacology.

[13]  B. Elliott,et al.  Review of the in vitro and in vivo genotoxicity of dichlorvos. , 2007, Regulatory toxicology and pharmacology : RTP.

[14]  John R. Bucher,et al.  Conflicting Views on Chemical Carcinogenesis Arising from the Design and Evaluation of Rodent Carcinogenicity Studies , 2007, Environmental health perspectives.

[15]  M. Dominick,et al.  Nonclinical Safety Evaluation of Muraglitazar, a Novel PPARα/γ Agonist , 2007 .

[16]  M. Fielden,et al.  A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  Harvey J Clewell,et al.  A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  A. Bittner,et al.  Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity , 2006, Molecular carcinogenesis.

[19]  A. Jacobs Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing? , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  Lutz Müller,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.

[21]  David Kirkland,et al.  Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo. , 2005, Mutation research.

[22]  L. Gold,et al.  Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  E. Boitier,et al.  Characterization of an acute molecular marker of nongenotoxic rodent hepatocarcinogenesis by gene expression profiling in a long term clofibric acid study. , 2005, Chemical research in toxicology.

[24]  A. Jacobs,et al.  Human carcinogenic risk evaluation, Part III: Assessing cancer hazard and risk in human drug development. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  Samuel M Cohen,et al.  Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  G Pearse,et al.  Prediction of Rodent Carcinogenesis: An Evaluation of Prechronic Liver Lesions as Forecasters of Liver Tumors in NTP Carcinogenicity Studies , 2004, Toxicologic pathology.

[27]  R. Maronpot,et al.  Relevance of Animal Carcinogenesis Findings to Human Cancer Predictions and Prevention , 2004, Toxicologic pathology.

[28]  J. Contrera,et al.  Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. , 2003, Regulatory toxicology and pharmacology : RTP.

[29]  Tomoyuki Shirai,et al.  A medium‐term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals , 2003, Cancer science.

[30]  J. Ashby,et al.  Prediction of rodent nongenotoxic carcinogenesis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens. , 2002, Environmental health perspectives.

[31]  I. Weissman,et al.  The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver. , 2001, Blood.

[32]  R. T. Bunch,et al.  The Syrian Hamster Embryo (SHE) Cell Transformation Assay: Review of the Methods and Results , 2001, Toxicologic pathology.

[33]  R. Montero,et al.  Genotoxic activity of praziquantel. , 1997, Mutation research.

[34]  S Parodi,et al.  Nongenotoxic carcinogens: development of detection methods based on mechanisms: a European project. , 1996, Mutation research.

[35]  H. Rosenkranz,et al.  Learning rules to predict rodent carcinogenicity of non-genotoxic chemicals. , 1995, Mutation research.

[36]  A. Monro,et al.  Marketed Human Pharmaceuticals Reported to be Tumorigenic in Rodents , 1995 .

[37]  J K Haseman,et al.  Comparative results of 327 chemical carcinogenicity studies. , 1987, Environmental health perspectives.

[38]  M. Tatematsu,et al.  Placental Glutathione S-Transferase (GST-P) as a New Marker for Hepatocarcinogenesis: In Vivo Short-Term Screening for Hepatocarcinogens , 1987, Toxicologic pathology.

[39]  Juan Riego Sintes,et al.  European experience in chemicals management: integrating science into policy. , 2011, Environmental science & technology.

[40]  Raffaella Corvi,et al.  ECVAM prevalidation of three cell transformation assays. , 2011, ALTEX.

[41]  H. Ellinger-Ziegelbauer,et al.  Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. , 2008, Mutation research.

[42]  M. Dominick,et al.  Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  Heidrun Ellinger-Ziegelbauer,et al.  Characteristic expression profiles induced by genotoxic carcinogens in rat liver. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[44]  G. Williams,et al.  Saccharin mechanistic data and risk assessment: urine composition, enhanced cell proliferation, and tumor promotion. , 1996, Pharmacology & therapeutics.

[45]  G. Williams,et al.  d-limonene mechanistic data and risk assessment: absolute species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. , 1996, Pharmacology & therapeutics.

[46]  J. Brown,et al.  Complementarity of genotoxic and nongenotoxic predictors of rodent carcinogenicity. , 1994, Teratogenesis, carcinogenesis, and mutagenesis.

[47]  J. Brown,et al.  Predicting rodent carcinogenicity of halogenated hydrocarbons by in vivo biochemical parameters. , 1993, Teratogenesis, carcinogenesis, and mutagenesis.